BQ Prime’s particular analysis part collates high quality and in-depth fairness and economic system analysis stories from throughout India’s prime brokerages, asset managers and analysis businesses. These stories supply BQ Prime’s subscribers a possibility to increase their understanding of firms, sectors and the economic system.
Prescription developments of key medication of Solar Pharmaceutical Industries Ltd. within the U.S. market point out strong progress momentum in key merchandise, together with Winlevi, Cequa and Ilumya.
We’ve got not seen any direct quantity affect put up the launch of generic Restasis on Cequa gross sales.
Solar Pharma was the primary generic participant to obtain U.S. Meals and Drug Administration approval for gAmbisome and gPentasa (500mg) within the U.S. market; the 2 merchandise have already been launched within the U.S. market and are gaining market share.
Solar Pharma held market share of ~70% in Sunitinib Malate on the finish of This autumn FY22; however, put up Viatris’ generic launch, the corporate has shed ~20% market share in Q1 FY23. Decline in prescription quantity of Levulan and Odomzo will even have an effect on Solar Pharma’s U.S. income in Q1 FY23.
Click on on the attachment to learn the complete report:
DISCLAIMER
This report is authored by an exterior get together. BQ Prime doesn’t vouch for the accuracy of its contents neither is answerable for them in any method. The contents of this part don’t represent funding recommendation. For that you need to all the time seek the advice of an professional based mostly in your particular person wants. The views expressed within the report are that of the writer entity and don’t characterize the views of BQ Prime.
Customers haven’t any license to repeat, modify, or distribute the content material with out permission of the Authentic Proprietor.